Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most ...

B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among ...

Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Tecartus demonstrated similar effectiveness across age groups of patients with relapsed or refractory B-cell acute ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed ...

standard-risk B-cell acute lymphoblastic leukemia (B-ALL), in a phase 3 randomized trial. Among pediatric patients with B-ALL ...

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

Chemotherapy and Blinatumomab improve survival rates in common childhood leukemia (B-cell acute lymphoblastic leukemia or B-ALL).

In a cohort of more than 300 patients with relapsed or refractory disease, 99.1% treated with the CD19/CD22-directed product ...